Status:
COMPLETED
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
Lead Sponsor:
Kirby Institute
Collaborating Sponsors:
St Vincent's Hospital, Sydney
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, pr...
Detailed Description
Antiretroviral medications, used to treat HIV infection, cause side effects. These include changes in composition of fat throughout the body (loss in some areas and accumulation in others), elevations...
Eligibility Criteria
Inclusion
- Age \>18.
- Be able to provide written consent to perform in the trial.
- HIV antibody positive at time of entry to the study.
- Specific to HIV Infection and Metabolic Abnormalities Protocol 1 (HAMA) part A only:
- Be naive to antiretroviral medication.
- Specific to HAMA part B only:
- Have had a minimum total exposure to antiretroviral medications (to include drugs from more than one drug class) of 48 weeks at time of recruitment.
- Have had a minimum of 48 weeks interval since completion of HAMA part A.
Exclusion
- Any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial.
- Prior use of growth hormone or glucocorticoid or anabolic steroid products within the previous six months.
- Prior use of supraphysiological doses of testosterone or oestrogen replacement therapy within the previous year.
- Alcohol or substance abuse which in the opinion of the investigator would affect the patients ability to participate in the trial.
- Prior use of any retinoid-containing compound within the previous six months.
- Abnormal coagulation.
- Previous allergic reaction or known allergy to local anaesthetic.
- Previous or concomitant use of medications, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial.
- Any grade-three laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements.
- Any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial.
- Pregnancy
- Specific to HAMA part A only:
- Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors). Entry of individuals who have had previous antiretroviral therapy as part of post exposure prophylaxis will be at the discretion of the study investigators.
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00192660
Start Date
February 1 2003
End Date
December 1 2007
Last Update
April 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Vincent's Hospital
Sydney, New South Wales, Australia, 2010